Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Maintaining Source Data Verification Logs – V 2.0

Posted on By

BA-BE Studies: SOP for Maintaining Source Data Verification Logs – V 2.0

Standard Operating Procedure for Maintaining Source Data Verification Logs in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/124/2025
Supersedes SOP/BA-BE/124/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To establish a consistent and regulatory-compliant procedure for maintaining Source Data Verification (SDV) logs in BA/BE studies to confirm data accuracy between source documents and case report forms (CRFs).

2. Scope

This SOP applies to all clinical research associates (CRAs), quality assurance staff, monitors, and site personnel responsible for verifying and documenting source data against study CRFs or electronic CRFs

during BA/BE studies.

3. Responsibilities

  • Clinical Research Associate (CRA): Performs SDV activities and records entries in the SDV log.
  • Principal Investigator (PI): Ensures availability of accurate and legible source documentation.
  • Study Coordinator: Assists in making all original source documents available for verification.
  • Quality Assurance: Reviews SDV logs for completeness and identifies potential discrepancies.
See also  BA-BE Studies: SOP for Documenting Protocol Violations and CAPA - V 2.0

4. Accountability

The Clinical QA Manager is accountable for ensuring SDV is systematically documented and reviewed in compliance with GCP and protocol requirements.

5. Procedure

5.1 Preparation for SDV

  1. Prior to the SDV visit, the CRA shall:
    • Obtain subject enrollment list and CRF pages from site.
    • Request availability of original source documents.
  2. Ensure all documents are anonymized and complete before initiating SDV.

5.2 SDV Log Maintenance

  1. Use Annexure-1: Source Data Verification Log to document each verification entry.
  2. Log shall capture:
    • Subject ID
    • Visit or timepoint
    • Data fields verified (e.g., vitals, lab reports, consent)
    • Verification status (Match/Discrepant)
    • Date and initials of verifier
  3. Discrepancies identified shall be flagged in the log and followed up with a data query (DQ) form.

5.3 Frequency and Coverage

  1. SDV shall be conducted:
    • During site initiation (partial SDV for training)
    • During interim monitoring (targeted or 100% SDV)
    • During closeout visit (final SDV)
  2. CRAs shall aim to complete SDV for at least 25–100% of subjects depending on the monitoring plan.
See also  BA-BE Studies: SOP for Ethics Committee Submission Requirements - V 2.0

5.4 SDV for Electronic Data

  1. For EDC (Electronic Data Capture) systems:
    • Login and access rights must be documented.
    • Print audit trails if applicable.
  2. Electronic records must comply with 21 CFR Part 11 or equivalent regulatory standard.

5.5 Post-SDV Follow-up

  1. All discrepancy resolutions must be documented and tracked in Annexure-2: SDV Discrepancy Resolution Log.
  2. SDV status for each subject shall be updated in Annexure-3: Subject SDV Status Tracker.
  3. Submit SDV summary report to sponsor/QA within 5 working days of visit.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • SDV: Source Data Verification
  • CRA: Clinical Research Associate
  • PI: Principal Investigator
  • CRF: Case Report Form
  • DQ: Data Query

7. Documents

  1. Source Data Verification Log – Annexure-1
  2. SDV Discrepancy Resolution Log – Annexure-2
  3. Subject SDV Status Tracker – Annexure-3
See also  BA-BE Studies: SOP for Clinical Phase Audit Preparation - V 2.0

8. References

  • ICH E6(R2) – Good Clinical Practice
  • US FDA Guidance on Source Data
  • 21 CFR Part 11 – Electronic Records

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Source Data Verification Log

Subject ID Visit Field Verified Status Date Verified By
V012 Day 0 Vitals, Consent Match 15/04/2025 Rajesh Kumar

Annexure-2: SDV Discrepancy Resolution Log

Subject ID Discrepancy Resolution Date Closed Resolved By
V014 Mismatch in BP reading Corrected CRF 16/04/2025 Sunita Reddy

Annexure-3: Subject SDV Status Tracker

Subject ID Screened Dosed SDV Completed Remarks
V010 Yes Yes Yes None

Revision History:

Revision Date Revision No. Details Reason Approved By
10/01/2022 1.0 Initial Release New SOP QA Head
17/04/2025 2.0 Included EDC-based SDV and audit trail reference ICH E6(R2) update QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: API Manufacturing: SOP for Destruction of Used IPC Samples – V 2.0
Next Post: Creams: SOP for Allergen Testing in Cream Products – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version